Complete Story
08/18/2026
Recent Oncology Related FDA Approvals and Expanded Indications
FDA Approves Bristol Myers Squibb's first CELMoD therapy ZENBEXUS™, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with Multiple Myeloma
FDA approves Merck's KEYTRUDA or KEYTRUDA QLEX, in combination with WELIREG, for the adjuvant treatment of adult patients with renal cell carcinoma
FDA approves Sanofi’s subcutaneous Sarclisa Escena anticancer treatment administered via on-body injector
FDA approves Lilly's selpercatinib (Retevmo) for locally advanced or metastatic RET fusion-positive solid tumors
FDA approves Celcuity's Revtorpyk™ (gedatolisib) for treatment of HR+/HER2-, PIK3CA Wild-Type locally advanced or metastatic breast cancer
More Info
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
